Trial Profile
An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Atazanavir; Darunavir; Fosamprenavir; Lopinavir; Ritonavir; Saquinavir
- Indications HIV-1 infections
- Focus Biomarker; Therapeutic Use
- Acronyms NEAT022 Study
- 12 Apr 2022 Results of a sub-study (n=86) assessed whether switching from a ritonavir-boosted PI-based regimen to a dolutegravir-based regimen improved the atherogenic properties of LDL particles in patients with HIV published in the Journal of Antimicrobial Chemotherapy
- 13 Jun 2021 Results of sub-study assessing 48 weeks changes in biomarkers published in the Journal of Antimicrobial Chemotherapy
- 31 Jul 2020 Results (n=156) assessing switching of boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk in sub-clinical CVD protocol, published in the Journal of Antimicrobial Chemotherapy.